SCHEMBL18214

SCHEMBL18214

O=C(O)c1cc(Br)ccc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
TP53 P04637 1/20 0.63
KDM4E B2RXH2 2/20 0.59
GLA P06280 1/20 0.59
MAPT P10636 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
POLB P06746 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SORT1 Q99523 1/20 0.53
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.50
PTPRC P08575 1/20 0.50
PTPRG P23470 1/20 0.50
DHODH Q02127 1/20 0.49
CYP1A2 P05177 1/20 0.49
MYC P01106 1/20 0.49
NR4A1 P22736 1/20 0.49
CTSB P07858 1/20 0.49
METAP2 P50579 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30249448 1.00 ALDH1A1 (0.63) ALDH1A1TP53KDM4EGLAMAPT
Hydrochloric Acid SCHEMBL1631822 0.98 ALDH1A1 (0.61) ALDH1A1TP53KDM4EGLAMAPT
SCHEMBL10462650 0.98 ALDH1A1 (0.61) ALDH1A1TP53KDM4EGLAMAPT
1,2-Dichloroethane SCHEMBL27883846 0.92 ALDH1A1 (0.55) ALDH1A1TP53KDM4EGLAMAPT
SCHEMBL17494763 0.86 ALDH1A1 (0.49) ALDH1A1TP53KDM4EGLAMAPT
SCHEMBL27299072 0.83 ALDH1A1 (0.58) ALDH1A1TP53KDM4EGLAMAPT
SCHEMBL29989222 0.83 TSHR (0.63) ALDH1A1TP53KDM4EGLASORT1
SCHEMBL30356385 0.83 ALDH1A1 (0.61) ALDH1A1KDM4EGLAMAPTPOLB
SCHEMBL28545012 0.83 ALDH1A1 (0.61) ALDH1A1KDM4EGLAMAPTPOLB
SCHEMBL18163 0.83 ALDH1A1 (0.61) ALDH1A1KDM4EGLAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059809-A Preparation method of dapagliflozin impurity 重庆圣华曦药业股份有限公司 2026-05-19 CN claimed
CN-120157566-A Synthesis method and application of dapagliflozin intermediate 江西华士药业有限公司 2025-06-17 CN claimed
US-20240351970-A1 PREPARATION METHOD OF 5-BROMO-2-CHLORO-BENZOIC ACID AS A SYNTHETIC RAW MATERIAL FOR HYPOGLYCEMIC DRUGS ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2024-10-24 US claimed
CN-118652170-A New synthesis method of 5-bromo-2-chlorobenzoic acid 宁夏法安德药业有限公司 2024-09-17 CN claimed
CN-117658784-B Dapagliflozin middle Process for the preparation of intermediates 山东诚汇双达药业有限公司 2024-09-13 CN claimed
CN-118420455-A Preparation method of 2-chloro-5-bromobenzoic acid 枣庄市润安制药新材料有限公司 2024-08-02 CN claimed
CN-118388436-A Preparation method of englitz intermediate and englitz impurity 江苏阿尔法药业股份有限公司 2024-07-26 CN claimed
EP-4389733-A1 METHOD FOR PREPARING 5-BROMO-2-CHLORO-BENZOIC ACID AS RAW MATERIAL IN HYPOGLYCEMIC DRUG SYNTHESIS Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) 2024-06-26 EP claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-113912487-B Synthesis method of 2, 5-dihalobenzoic acid 山东研峰新材料科技有限公司 2024-05-28 CN claimed
WO-2008079225-A1 PROCESS FOR THE SYNTHESIS OF ETHERS OF AROMATIC ACIDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-07-03 WO claimed
WO-2008079218-A1 PROCESS FOR THE SYNTHESIS OF ETHERS OF AROMATIC ACIDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-07-03 WO claimed
CN-100357245-C Prepn process of 2,5-dihalogeno benzoic acid DALIAN LUYUAN PHARMACEUTICAL I (CN) 2007-12-26 CN claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351970-A1 PREPARATION METHOD OF 5-BROMO-2-CHLORO-BENZOIC ACID AS A SYNTHETIC RAW MATERIAL FOR HYPOGLYCEMIC DRUGS GABRA5, DDC, GCG ALDH1A1 1171/4885TP53 2351/4885KDM4E 778/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 ALDH1A1 1569/4885TP53 548/4885KDM4E 1814/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 ALDH1A1 1723/4885TP53 499/4885KDM4E 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.